title: Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
abstract: Ebola virus (EBOV) causes lethal disease in up to 90% of EBOV-infected humans. Among vaccines, only the vesicular stomatitis virus platform has been successful in providing postexposure protection in nonhuman primates. Here, we show that an adjuvanted human adenovirus serotype 5 (Ad5)-vectored vaccine (Ad5-Zaire EBOV glycoprotein) protected 67% (6 of 9) and 25% (1 of 4) of cynomolgus macaques when administered 30 minutes and 24 hours following EBOV challenge, respectively. The treatment also protected 33% of rhesus macaques (1 of 3) when given at 24 hours. The results highlight the utility of adjuvanted Ad5 vaccines for rapid immunization against EBOV.
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology.
authors.forename: Gary
authors.initials: G
authors.lastname: Wong
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada.
authors.forename: Jason S
authors.initials: JS
authors.lastname: Richardson
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Pillet
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada.
authors.forename: Trina
authors.initials: T
authors.lastname: Racine
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology.
authors.forename: Ami
authors.initials: A
authors.lastname: Patel
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada.
authors.forename: Geoff
authors.initials: G
authors.lastname: Soule
authors.affiliation: Defyrus, Toronto, Canada.
authors.forename: Jane
authors.initials: J
authors.lastname: Ennis
authors.affiliation: Defyrus, Toronto, Canada.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Turner
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology.
authors.forename: Xiangguo
authors.initials: X
authors.lastname: Qiu
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada Department of Medical Microbiology Department of Immunology, University of Manitoba, Winnipeg Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia.
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000258:Adenovirus Infections, Human / Q000276:immunology / Q000821:virology; D000260:Adenoviruses, Human / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D046129:Ebola Vaccines / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology*; D005822:Genetic Vectors / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000821:virology; D006801:Humans; D008252:Macaca fascicularis / Q000276:immunology* / Q000821:virology; D008253:Macaca mulatta / Q000276:immunology* / Q000821:virology; D014611:Vaccination / Q000379:methods
chemical_list: D000914:Antibodies, Viral; D046129:Ebola Vaccines
keywords: Ebola; adenovirus; nonhuman primates; post-exposure; vaccine